gene-environment interaction - Mediterranean School of ：基因-环境交互作用-地中海学院.pptVIP

Analysis in 435 out of 755 patients in the CAIRO-2 study Which patients from the CAIRO-2? VEGF production seems important in the early stages, while progression is accompanied by altered production of other angiogenic factors VEGFPIGFPDGF bFGFIL-8 Analysis of Circulating Levels Progression? Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies. Bernaards C et al Abstr 10519 AVF2107g(colorectal) AVAiL(NSCLC) AVOREN(Renal cell) Baseline VEGF levels in 1816 patients from Higher circulating VEGF levels were associated with shortened PFS and overall survival regardless of bevacizumab treatment The distributions of circulating VEGF levels were similar across the tumor types Measurement of baseline circulating VEGF levels may be useful as a prognostic biomarker, but not as a predictive biomarker for bevacizumab-based treatment benefit in metastatic colorectal, lung, and renal cell cancers. Neither the baseline levels of VEGF nor those of VEGFR2 were associated with differences in PFS or OS, but…… Dynamic changes of cytokine levels…… * * * In conclusion……..where do we stand? VEGF polys hypertension IL-8 DCE-NMR PDGF MMP-9 bFGF * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * VEGF inhibitors: predictive markers and biological insights Dr. Francesco Graziano Dipartimento di Onco-Ematologia, SOC Oncologia Azienda Ospedaliera “Ospedali Riuniti Marche Nord” ANTI VEGF/VEGF-R Monoclonal Abs - Bevacizumab (VEGF) - IMC-IC11 (VEGF-R2) - VEGF-trap (soluble rec.) VEGF-R TKI - PTK787/ZK222 584 - SU11248 - BAY43-9006 - AG013736 - ZD 6474 - CP-547, 632 MMPS INHIBITORS - Marimastat - Prinomastat ANTI ENDOTHELIAL CELLS - Angyostatin - Endostatin - TNP 470 - Thalidomide Displaying the battlefield……. …… an example of what survival curves say in metastatic colo